Clinical Trial Update: Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration [Phase 1, Phase 2]

View source ↗

Summary

The study completed Phase 1/2 evaluating Lucentis (ranibizumab) for retinal angiomatous proliferation secondary to age-related macular degeneration. It reported…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Retinal Angiomatous Proliferation

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: The National Retina Institute | Conditions: Macular Degeneration | Phase 1, Phase 2 | Status: COMPLETED